{'fraction_non_alphanumeric': 0.03118279569892473, 'fraction_numerical': 0.007526881720430108, 'mean_word_length': 5.795620437956204, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Principles of treatment and military medical examination of the patients with indolent Non-Hodgkin's lymphomas].

Non-Hodgkin's lymphomas (NHL) are the heterogeneous group of lymphoproliferative malignancies with distinct morphological, immuno-histochemical and genetic criteria of diagnosis, different character of clinical course, sensitivity to different treatment methods and disease prognosis. The WHO classification (1997) encompasses all the lymphoproliferative neoplasms. The NHL can be divided into 2 prognostic groups: the indolent lymphomas and the aggressive non-Hodgkin's lymphomas. The indolent NHL types have a relatively favorable clinical prognosis, with median survival as long as 10 years, but they usually are not curable in advanced clinical stages. Early-stage (I and II) indolent NHL can be effectively treated with radiation therapy alone. In advanced stages of indolent NHL the chemotherapy is conducted.